CLEVELAND, April 1 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced NTT DATA, its strategic partner in Japan, has signed its first Enterprise Transfer client. DATATRAK and NTT DATA have extended their business relationship to allow NTT DATA to sell Enterprise Transfer services within the Japanese market which will produce additional revenue streams for both companies. NTT DATA successfully closed a multi-year enterprise deal with one of its existing clients who will be using DATATRAK eClinical(TM) for all trials after April 2010.
Under DATATRAK’s Enterprise Transfer Program, clients can be fully empowered to manage all aspects of their trials or only choose to manage those areas within their core competencies. Enterprise Transfer allows clients to undertake the trial design, user administration and training of their clinical trials. DATATRAK offers a certified training program and tier two support to help sustain Enterprise Transfer clients.
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management’s expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company’s performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company’s quarterly results; the viability of the Company’s business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company’s dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other’s intellectual property rights; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company’s success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.
CONTACT: Varnesh Sritharan, Vice President of Legal Affairs, DATATRAK
International, Inc., +1-440-443-0082 x 143
Web site: http://www.datatrak.net/
